Bulbine natalensis (currently Bulbine latifolia) and select bulbine knipholones modulate the activity of AhR, CYP1A2, CYP2B6, and P-gp

Abstract

Bulbine natalensis, an emerging medicinal herb on the global market with androgenic properties, is often formulated in dietary supplements that promote perceived sexual enhancement. However, to date, comprehensive safety studies of B. natalensis are lacking, particularly those related to its herb-drug interaction potential. The purpose of this study was to assess the inductive and inhibitory effects of extracts and pure compounds of B. natalensis on human cytochrome P-450 isozymes in vitro. Our findings demonstrated that both water and methanolic extracts of B. natalensis as well as knipholone, bulbine-knipholone, and 6′-O-methylknipholone dose-dependently increased mRNA expression encoded by CYP2B6, CYP1A2, and ABCB1 genes. Functional analyses showed that water (60 to 2.20 µg/mL) and methanolic (30 to 3.75 µg/mL) extracts and knipholones (10 to 0.33 µM) increased CYP2B6 and CYP1A2 activity in a dose-dependent manner. Additionally, water extract (60 µg/mL), methanolic extract (30 µg/mL), and knipholone (10 µM) caused activation of the aryl hydrocarbon receptor up to 11.1 ± 0.7, 8.9 ± 0.6, and 7.1 ± 2.0-fold, respectively. Furthermore, inhibition studies revealed that methanolic extract attenuated the activity of metabolically active CYP1A2 (IC₅₀, 22.6 ± 0.4 µg/mL) and CYP2B6 (IC₅₀, 34.2 ± 6.6 µg/mL) proteins, whereas water extracts had no inhibitory effect on either isoform. These findings suggest that chronic consumption of B. natalensis may affect normal homeostasis of select CYPs with subsequent risks for HDIs when concomitantly ingested with conventional medications that are substrates of CYP2B6 and CYP1A2. However, more in-depth translational studies are required to validate our current findings and their clinical relevance.

Key words

Bulbine natalensis - aryl hydrocarbon receptor - cytochrome P-450s - herb-drug interactions - anthraquinones - mRNA expression - CYP inhibition - Xanthorrhoeaceae

^# Currently at Covance Inc., Salt Lake City, Utah, United States

Publikationsverlauf

Eingereicht: 23. April 2021

Angenommen nach Revision: 18. Juli 2021

Artikel online veröffentlicht:
06. August 2021

• References

• 1 Musara C, Aladejana EB. Review of studies on Bulbine natalensis Baker (Asphodelaceae): ethnobotanical uses, biological and chemical properties. J Appl Pharm 2020; 10: 150-155
• 2 Yakubu MT, Afolayan AJ. Effect of aqueous extract of Bulbine natalensis (Baker) stem on the sexual behaviour of male rats. Int J Androl 2009; 32: 629-636
• 3 Bae JY, Ali Z, Wang YH, Chittiboyina AG, Zaki AA, Viljoen AM, Khan IA. Anthraquinone-based specialized metabolites from rhizomes of Bulbine natalensis . J Nat Prod 2019; 82: 1893-1901
• 4 European Commission. Novel Food Catalogue. Brussels, Belgium: European Commission; 2020
• 5 (LNHPD) Licensed Natural Health Products Database. Natural and Non-prescription Health Products Directorate. Ottawa, ON, Canada: Health Canada; 2020
• 6 Dietary Supplement Label Database (DSLD). Office of Dietary Supplements and the National Library of Medicine. Bethesda, MD: National Institutes of Health; 2020
• 7 Cederbaum AI. Molecular mechanisms of the microsomal mixed-function oxidases and biological and pathological implications. Redox Biol 2015; 4: 60-73
• 8 Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009; 61: 541-558
• 9 Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995; 35: 307-340
• 10 Busbee PB, Rouse M, Nagarkatti M, Nagarkatti PS. Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutr Rev 2013; 71: 353-369
• 11 Nebert DW. Aryl hydrocarbon receptor (AHR): “pioneer member” of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of “sensors” of foreign and endogenous signals. Prog Lipid Res 2017; 67: 38-57
• 12 Gurley BJ, Yates CR, Markowitz JS. “…Not intended to diagnose, treat, cure, or prevent any disease.” 25 years of botanical dietary supplement research and the lessons learned. Clin Pharmacol Ther 2018; 104: 470-483
• 13 US-FDA guideline 2020. In vitro drug interaction studies – cytochrome P450 enzyme- and transporter-mediated drug interactions: Guidance for industry. Accessed July 28, 2021 at: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
• 14 Husain I, Manda V, Alhusban M, Dale OR, Bae JY, Avula B, Gurley BJ, Chittiboyina AG, Khan IA, Khan SI. Modulation of CYP3A4 and CYP2C9 activity by Bulbine natalensis and its constituents: An assessment of HDI risk of B. natalensis-containing supplements. Phytomedicine 2021; 81: 153416
• 15 Eichhorn T, Greten HJ, Efferth T. Self-medication with nutritional supplements and herbal over-the-counter products. Nat Prod Bioprospect 2011; 1: 62-70
• 16 Koe XF, Muhammad TST, Chong AS, Wahab HA, Tan ML. Cytochrome P450 induction properties of food and herbal-derived compounds using a novel multiplex RT-qPCR in vitro assay, a drug-food interaction prediction tool. Food Sci Nutr 2014; 2: 500-520
• 17 Gouws C, Hamman JH. What are the dangers of drug interactions with herbal medicines?. Expert Opin Drug Metab Toxicol 2020; 16: 165-167
• 18 Xie W, Evans RM. Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 2001; 276: 37739-37742
• 19 Moore LB, Goodwin B, Jones SA, Wisely GB, Singh CJS, Willson TM, Collins JL, Kliewer SA. St. Johnʼs wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci 2000; 97: 7500-7502
• 20 Manda VK, Avula B, Olivia RD, Ali Z, Khan IA, Walker LA, Khan SI. PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids. Phytother Res 2017; 31: 1935-1945
• 21 Yakubu MT, Afolayan AJ. Anabolic and androgenic activities of Bulbine natalensis stem in male Wistar rats. Pharm Biol 2010; 48: 568-576
• 22 Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003; 43: 309-334
• 23 Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141
• 24 Kapelyukh Y, Henderson CJ, Scheer N, Rode A, Wolf RC. Defining the contribution of CYP1A1 and CYP1A2 to drug metabolism using humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 knockout mice. Drug Metab Dispos 2019; 47: 907-918
• 25 Netsch MI, Gutmann H, Schmidlin CB, Aydogan C, Drewe J. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med 2006; 72: 514-520
• 26 Fasinu PS, Bouic PJ, Rosenkranz B. The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19, and 3A4 and the implications for herb-drug interaction. Afr J Tradit Complement Altern Med 2014; 11: 54-61
• 27 Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008; 21: 70-83
• 28 Kang P, Dalvie D, Smith E, Zhou S, Deese A, Nieman JA. Bioactivation of flutamide metabolites by human liver microsomes. Drug Metab Dispos 2008; 36: 1425-1437
• 29 Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6, and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007; 100: 23-30
• 30 Silva SM, Martinho A, Moreno I, Silvestre S, Granadeiro LB, Alves GA, Duarte AP, Domingues F, Gallardo E. Effects of Hypericum perforatum extract and its main bioactive compounds on the cytotoxicity and expression of CYP1A2 and CYP2D6 in hepatic cells. Life Sci 2016; 144: 30-46
• 31 Manda VK, Ibrahim MA, Dale OR, Kumarihamy M, Cutler S, Khan IA, Walker LA, Muhammad I, Khan SI. Modulation of CYPs, P-gp, and PXR by Eschscholzia californica (California Poppy) and its alkaloids. Planta Med 2016; 82: 551-558
• 32 Lim EL, Seah TC, Koe XF, Wahab HA, Adenan MI, Jamil MFA, Majid MIA, Tan ML. In vitro evaluation of cytochrome P450 induction and the inhibition potential of mitragynine, a stimulant alkaloid. Food Chem Toxicol 2013; 68: 117-127
• 33 Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 2013; 4: 24
• 34 Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity-based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999; 27: 655-666
• 35 Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 2002; 301: 945-952
• 36 Wang D, Li L, Yang H, Ferguson SS, Baer MR, Gartenhaus RB, Wang H. The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies. Blood 2013; 121: 329-338
• 37 Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488-1495
• 38 Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300
• 39 Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T. Involvement of CYP2B6 in N-Demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001; 29: 887-890
• 40 Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 2010; 62: 1238-1249
• 41 Fasinu PS, Manda VK, Dale OR, Egiebor NO, Walker LA, Khan SI. Modulation of cytochrome P450, P-glycoprotein and pregnane X receptor by selected antimalarial herbs-implication for herb-drug interaction. Molecules 2017; 22: 2049
• 42 Fantoukh OI, Dale OR, Parveen A, Hawwal MF, Ali Z, Manda VK, Khan SI, Chittiboyina AG, Viljoen A, Khan IA. Safety assessment of phytochemicals derived from the globalized south African rooibos tea (Aspalathus linearis) through interaction with CYP, PXR, and P-gp. J Agric Food Chem 2019; 67: 4967-4975
• 43 Liu C, Lim Y, Hu M. Fucoxanthin attenuates rifampin induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 2012; 10: 242-257
• 44 Zheng YF, Bae SH, Choi EJ, Park JB, Kim SO, Jang MJ, Park GH, Shin WG, Oh E. Bae SK. Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its 4 bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition. Food Chem Toxicol 2014; 68: 117-127
• 45 Husain I, Sharma A, Kumar S, Malik F. Purification and characterization of glutaminase free asparaginase from Pseudomonas otitidis: Induce apoptosis in human leukemia MOLT-4 cells. Biochimie 2016; 121: 38-51